BIOSIMILYaRY: PROBLEMY ZAMEShchENIYa I SOVREMENNYE TREBOVANIYa K VOSPROIZVEDENNYM PREPARATAM INSULINA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To date, numerous studies have convincingly proved significant differences in the efficacy and safety of treatment between the original and generic biotechnological drugs (biosimilars). However, despite abundant evidence of therapeutic inequivalence, there is a problem of “automatic" replacement of original drugs on biosimilars due to lower cost. This situation calls for the revision of the legal framework governing the circulation of biosimilars our country.

Full Text

Restricted Access

References

  1. The Commission of the European Communities (2003) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. In Official Journal of the European Union, L159, pp. 46-94. (http://eur-lex.europa.eu/lexUriServ/lexUriServ. do ?uri =0J:L:2003:159:0046:0094:EN:PDF).
  2. Azevedo VF. Are we prepared to prescribe biosimi-lars? Bras J Rheumatol 2010;50(3):221 -24.
  3. Kresse G-B. Biosimilars - Science, status, and strategic perspective. Eur J Pharm Biopharm 2009;72(3) :479-86.
  4. Kuhlmann M. Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21 (Suppl. 5):v4-v8. doi: 10.1093/ndt/gfl474.
  5. Misra A. Are biosimilars really generics? Expert Opin Biol Ther 2010;10(4):489-94.
  6. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol 2008; 39:113-18.
  7. Шестакова М.В., Викулова О.К. Биосимиляры: презумпция "виновности" // Сахарный диабет 2011;4(53):91-9.
  8. Home P. Biosimilar insulins. Diabetes Voice 2011;56(2):41-3.
  9. Schellekens H. Biosimilar therapeutics - what do we need to consider? NDT Plus 2009; (Suppl. 1): i27-i36. doi: 10.1093/ndtplus/sfn177.
  10. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antieryth-ropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
  11. Raditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney International 2011;80:88-92;doi:10.1038/ ki.2011.68.
  12. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011;3(2):209-17.
  13. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010;10:90-7.
  14. European Medicines Agency Withdrawal Assessment Report for Insulin Human 30/70 Mix Marvel 2008. http://www.ema.europa.eu/humandocs/PDFs/EPAR/ insulinhumanrapidmarvel/701790en.pdf. Accessed 12 May 2010.
  15. European Medicines Agency Withdrawal Assessment Report for Insulin Human Rapid Marvel, 2007; http:// www.ema.europa.eu/humandocs/PDFs/EPAR/insu linhumanrapidmarvel/31777807en.pdf. Accessed 12 May 2010.
  16. European Medicines Agency Withdrawal Assessment Report for Insulin Human Long Marvel. 2008; http:// www.ema.europa.eu/humandocs/PDFs/EPAR/insulinh umanrapidmarvel/7034908en.pdf. Accessed 12 May 2010.
  17. Lispi M, Datola A, Bierau H, et al. Heterogeneity of commercial recombinant human growth hormone (r-hGH) preparations containing a thioether variant. Journal of Pharmaceutical Sciences 2009;98(12):4511-24. doi: 10.1002/jps.21774.
  18. Singh AK. Biosimilar epoetins: potential for variation reinforces need for regulation. Nephrology Times 2008;1(4):2-14.
  19. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004;3:8-12.
  20. Buehler GJ, Conner D. The FDA Process for Approving Generic Drugs. FDA Office of Generic Drugs. http:// www.connectlive. com/events/genericdrugs/2006.
  21. Questions and answers on generic medicines. EMEA document. EMEA/393905/2006. London, UK: European Medicines Agency, 2007. Available from: www.emea.europa.eu/pdfs/ human/pcwp/39390506en.pdf [Last accessed 30 January 2010].
  22. European Medicines Agency. Guideline on Similar Biological Medicinal Products, CPMP/437/04, October 2005. www.ema.europa.eu/pdfs/human/ biosimilar/043704en Accessed 29 April 2010.
  23. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance - Non Clinical and Clinical Issues, EMEA/CHMP/BMWP/42832/05, February 2006. www.ema.europa.eu/pdfs/human/ biosimilar/4283205en Accessed 02 September 2010.
  24. European Medicines Agency. Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Quality Issues, CHMP/49348/05, February 2006. www.ema.europa.eu/pdfs/human/ biosimilar/4934805en Accessed 02 September 2010.
  25. European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins. EMEA/CHMP/ BMWP/14327/2006, December 2007. http://www. ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/09/WC500003946.pdf. Accessed 02 September 2010.
  26. European Medicines Agency. Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology derived Proteins as Drug Substance - Non Clinical and Clinical Issues. Guidance on Similar Medicinal Products Containing Recombinant Human Insulin CHMP/ BMWP/32775/05, February 2006. www.ema.europa. eu/pdfs/human/biosimilar/3277505en. Accessed 02 September 2010.
  27. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues EMEA/CHMP/BMWP/32775/2005_ Rev. 1, Committee for Medicinal products for Human (CHMP). EMA/134217/2012, 13 December 2012.
  28. Marvel's withdrawal letter, 15 November 2012, EMA press release, 27 November 2012 and CI news.
  29. http://www.ema.europa.eu/docs/en_GB/document_ library/Application_withdrawal_assessment_ report/2013/02/WC500138884.pdf). Last access 20.03.2013
  30. Cheng SW, Lu JM, Pan CU, et al. Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man [in Chinese]. Chin J Diabetes 2010;18:387-93.
  31. Zhu L, He L, Gu Q, Zhang Y, Zou D. A study on the control of fasting and postprandial hyperglycemia by glargine insulin combined with oral hypoglycemic agent [in Chinese]. Chin J Diabetes 2009; 17:690-92.
  32. Verma M, Hazra P, Iyer H, et al. Basalog_ is similar to Lantus_ in producing glycemic control in patients with type1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Countries 2011;31:26-31.
  33. Instituto Nacionalde Vigilanciade Medicamentosy Alimentos: Sala especializada de medicamentos y productos biolo' gicos de la comisio'n revisora, Acta No. 31. Ministeriode la Proteccio'n Social, Bogata, Repu' blicade Colombia. 2009.http://web.invima.gov. co/portal/documents/portal/documents/root/acta 312009_medicamentos.pd (accessed August 2012).
  34. Schmidt A, Schaefer E, Schmeier E, Jochum M. By-product profile of insulin glargine preparations: a fingerprint of the biotechnological production process [abstract P-1429]. Presented at the World Diabetes Congress of the International Diabetes Federation, Dubai, 2011.
  35. Kannan V, Narayanaswamy P, Gadamsetty D, Hazra P, Khedkar A, Iyer H: A tandem mass spectrometric approachto the identification of O-glycosylated glargine glycoforms in active pharmaceutical ingredient expressed in Pichia pastoris. Rapid Commun Mass Spectrom 2009;23:1035-12.
  36. Li J, Liang C, Zhang H, Yang H, Wang D: Structural identification and qualitative analysis of recombinant insulin glargine-related impurities [in Chinese; English abstract]. Chin Pharm J 2008;43:1-12.
  37. Weise M, Bielsky M-C, De Smet K, Ehmann F, et al. Biosimilars - why terminology matters. Nature biotechnology 2011;29(8):690-93.
  38. WHO Technical Report Series, No. 937, 2006. Gidelines on registration requirements to establish intergeability.
  39. Дорофеев В.Л. Подходы к оценке взаимозаменяемости лекарственных средств. Ремедиум декабрь 2011. С. 51-7.
  40. Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The Emergence of Biosimilar Insulin Preparations - A Cause for Concern? Diabetes Technology& Therapeutics 2012;14(11):1-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies